<DOC>
	<DOCNO>NCT01910025</DOCNO>
	<brief_summary>Certain cancer require amino acid arginine . Arginine deiminase ( ADI ) enzyme microbe degrade arginine . ADI formulate polyethylene glycol use treat patient cancer arginine . In study , primary efficacy variable assessment tumor response rate .</brief_summary>
	<brief_title>PH 2 ADI-PEG 20 Study Non-Hodgkin 's Lymphoma Subjects Who Have Failed Prior Systemic Therapy</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>INCLUSION CRITERIA 1 . Histologically proved NHL ( B T cell ) accord WHO criteria relapse refractory least 2 prior systemic chemotherapy ( exclude chronic lymphocytic leukemia Waldenstrom 's macroglobulinemia ) . 2 . Measurable disease assess IHP criterion ( Appendices A B ) . 3 . Age ≥ 20 year . 4 . ECOG performance status 02 . 5 . No prior systemic therapy , immunotherapy , investigational agent , radiation therapy within last 2 week prior first dose study treatment . 6 . Fully recover prior surgery major surgery within 4 week initiate treatment . Surgery placement vascular access device acceptable . 7 . Postmenarche female subject male subject must ask use appropriate contraception male female duration study . Subjects must agree use two form contraception agree refrain intercourse duration study . Females must pregnant start study , serum human chorionic gonadotropin ( HCG ) pregnancy test must negative entry study . 8 . Informed consent must obtain prior study initiation . 9 . No concurrent investigational study allow . 10 . Absolute neutrophil count ( ANC ) &gt; 750/µL . 11 . Platelets &gt; 50,000/µL . 12 . Serum uric acid ≤ 8 mg/dL ( without medication control ) . 13 . Creatinine clearance must ≥ 30 mL/min . This calculated use CockcroftGault equation : estimate creatinine clearance = [ ( 140 age ) x weight ( kg ) ] / serum creatinine ( mg/dl ) x 72 ; female , multiple result 0.85 . EXCLUSION CRITERIA A subject eligible study participation he/she meet exclusion criterion : 1 . Patients infection require intravenous ( IV ) antibiotic/antiviral therapy eligible entry onto study ; patient prophylactic antibiotic antiviral acceptable . 2 . Pregnancy lactation . 3 . Expected noncompliance . 4 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure ( New York Heart Association Class III IV ) , cardiac arrhythmia , psychiatric illness , social situation would limit compliance study requirement . 5 . Subjects anticancer treatment prior enter study recover baseline ( except alopecia ) ≤ Grade 1 AEs , deem irreversible effect prior cancer therapy . AEs &gt; Grade 1 consider safety risk Sponsor investigator may allow upon agreement . 6 . Subjects history another primary cancer , include coexistent second malignancy , exception : ) curatively resect nonmelanoma skin cancer ; b ) curatively treated cervical carcinoma situ ; c ) primary solid tumor know active disease present opinion investigator affect patient outcome set current ASS negative cancer diagnosis . 7 . Subjects treat ADIPEG 20 previously . 8 . History seizure disorder relate underlying cancer . 9 . Known HIV positivity ( test require ) . 10 . Autologous allogenic stem cell transplantation within 3 month first dose study treatment . 11 . Systemic steroid stabilize equivalent ≧ 15 mg/day prednisone 7 day prior first dose study treatment . 12 . CNS lymphoma . 13 . Allergy pegylated compound .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Argininosuccinate Synthetase</keyword>
	<keyword>Arginine</keyword>
	<keyword>Arginine deiminase</keyword>
</DOC>